BCG’s health care industry experts will be on the ground in San Francisco January 13 through 15 joining the J.P. Morgan Healthcare Conference to share insights on trends shaping the industry now and in the year ahead.
The J.P. Morgan Healthcare Conference is the largest health care investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. BCG is thrilled to be back in San Francisco with programming coinciding with this year’s conference to explore the latest trends impacting the industry.
We’ll be in San Francisco during the 2025 J.P. Morgan Healthcare Conference to connect with R&D, business, and corporate development leaders on the 2025 outlook for the health care industry. Our experts bring a wealth of experience and deep expertise on topics at the forefront of health care leaders’ agendas in the year ahead, including:
Explore our latest thinking on topics impacting the health care industry.
New GenAI offerings can benefit virtually every aspect of an organization, boosting efficiency and productivity in areas ranging from R&D to commercial activities.
The technology is evolving rapidly, but five simple steps can help providers capitalize on GenAI to improve performance, reduce costs, and enhance the experience for patients and staff.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
Leaders need to understand the growing range of AI applications—and how to capitalize on their potential while avoiding the risks.
BCG experts interview one of the world’s largest biopharmaceutical companies to discuss their bold “Play to Win” strategy and the role of AI in innovation.
BCG sits down in an interview with Richard Francis, CEO of Teva, to discuss the company’s bold and thoughtful strategy for advancing health care.
CCO Everett Cunningham sits down with BCG’s Torben Danger to explain how Exact Sciences is addressing the challenges of spreading colon cancer awareness.
BCG’s new annual report identifies the modalities that are progressing most rapidly and those that hold the greatest promise for patient outcomes and company revenues.
Three new provisions concerning Medicare prescription drug prices have major ramifications for companies and the broader health care ecosystem.
To retain target biotech company employees—arguably as vital to success as the pipeline being acquired—biopharmas need talent strategies that focus on three key areas.
Medtech management teams face an unfamiliar list of questions. The players that can successfully navigate the challenging terrain will be the winners of the 2020s.
Rather than focusing on discrete products, companies should develop platforms based on modular designs, with hardware and software that can be continuously upgraded.
Medical technology companies play a big part in health care’s carbon emissions problem, both at the patient and provider levels. Fortunately, these firms can reduce their footprint affordably.
While digital, data, and AI have extraordinary potential to revolutionize our global health care systems, they have yet to deliver a transformative impact. How can the public and private sectors accelerate progress?
Some of BCG's best advice to help provider, payer, biopharma, and medtech executives address the challenges and changes affecting the health care sector.
The latest technologies hold tremendous promise for health care, but they also pose significant challenges. Not all organizations are prepared to take advantage of the tech trends.
A suite of improvement levers provides the basis for designing a health care payers’ customized productivity transformation.
As the market recovers in 2024, multiple trends affecting providers, payers, pharma, medtech, and life science tools will shape how private equity investors plan to play.
Experts across BCG and BCG X foresee an exciting year of technology advances in areas such as at-home care, women’s health, and mental well-being.
